$3995 | Single User
$7990 | Site License
$11985 | Enterprise License

EpiCast Report: Heart Failure - Epidemiology Forecast to 2025
[Published by Global Data]

Published by Global Data: 01 May 2016 | 26671 | In Stock
Related Topics: Cardiology , Heart Failure

Introduction

EpiCast Report: Heart Failure - Epidemiology Forecast to 2025

Summary

Heart Failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body. Eventually, without the heart's pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. HF commonly occurs in people above 50 years of age, and severity increases progressively with age. Symptoms can develop quickly, such as in acute HF, at which time the patient needs to be hospitalized. However, in chronic HF, the symptoms develop gradually. Due to the chronic nature of cardiovascular diseases, many of the risk factors for HF, such as chronic obstructive pulmonary disease (COPD) and anemia, are also comorbid conditions.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HF will increase from 1,094,344 cases in 2015 to 1,400,377 cases in 2025 at an Annual Growth Rate (AGR) of 2.80%. In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of chronic HF will increase from 13,756,453 cases in 2015 to 16,105,489 cases in 2025 at an AGR of 1.71%. The US will have the highest number of diagnosed incident cases of HF and diagnosed prevalent cases of chronic HF among the 7MM throughout the forecast period with 1,052,831 diagnosed incident cases of HF and 6,170,142 diagnosed prevalent cases of chronic HF in 2025. In the 7MM in 2015, 37.59% of the diagnosed prevalent cases of chronic HF are in NYHA Class I, 39.54% in NYHA Class II, 19.11% in NYHA Class III, and 3.75% in NYHA Class IV.

GlobalData epidemiologists utilized comprehensive, country-specific data from national HF registers and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed incident cases of HF, as well as the diagnosed prevalent cases of chronic HF. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for diagnosed incident and diagnosed prevalent cases of HF. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful global comparisons of the diagnosed incident and diagnosed prevalent cases of HF across these markets.

Scope

- The Heart Failure (HF) EpiCast Report provides an overview of the risk factors and global trends of HF in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of HF diagnosed incident and diagnosed prevalent cases segmented by age and sex. Diagnosed incident cases are further segmented by ejection fraction, ventricular dysfunction, acute HF hospitalizations (by worsening HF, advanced HF, de novo HF), re-admissions (within 3 months) post-discharge after acute HF hospitalization, and hospital length of stay for acute HF hospitalization in these seven markets. Diagnosed prevalent cases are further segmented by chronic HF (by ejection fraction), and also classified according to the New York Heart Association (NYHA) functional classes I-IV, and American College of Cardiology Foundation/American Heart Association (ACCF/AHA) stages B, C and D in these seven markets.

- The HF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The HF EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global HF market.

- Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.

- Identify the percentage of HF diagnosed incident and diagnosed prevalent cases by various clinical segmentations.

Table of Contents
for EpiCast Report: Heart Failure - Epidemiology Forecast to 2025 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 5

    1.1 List of Tables 6

    1.2 List of Figures 7

    2 Epidemiology 9

    2.1 Disease Background 9

    2.2 Risk Factors and Comorbidities 10

    2.3 Global Trends 12

    2.3.1 US 12

    2.3.2 5EU 13

    2.3.3 Japan 14

    2.4 Forecast Methodology. 15

    2.4.1 Sources Used Tables 17

    2.4.2 Forecast Assumptions and Methods 20

    2.4.3 Sources Not Used 35

    2.5 Epidemiological Forecast for HF (2015-2025) 36

    2.5.1 Diagnosed Incident Cases 36

    2.5.2 Diagnosed Prevalent Cases 49

    2.6 Discussion 61

    2.6.1 Epidemiological Forecast Insight 61

    2.6.2 Limitations of the Analysis 61

    2.6.3 Strengths of the Analysis 62

    3 Appendix 63

    3.1 Bibliography 63

    3.2 About the Authors 72

    3.2.1 Epidemiologists 72

    3.2.2 Reviewers 72

    3.2.3 Global Director of Therapy Analysis and Epidemiology 73

    3.2.4 Global Head of Healthcare 74

    3.3 About GlobalData 75

    3.4 About EpiCast 75

    3.5 Disclaimer 76

List Of Tables
in EpiCast Report: Heart Failure - Epidemiology Forecast to 2025 [Published by Global Data]

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for HF 11

Table 2: NYHA Functional Classes I-IV 16

Table 3: ACCF/AHA Stages A, B, C, and D 17

Table 4: 7MM, Sources of Epidemiological Data Used for the Forecast of HF Diagnosed Incident Cases 17

Table 5: 7MM, Sources of Epidemiological Data Used for the Forecast of Chronic HF Diagnosed Prevalent Cases 18

Table 6: 7MM, Sources of Epidemiological Data Used for the Classification of Diagnosed Prevalent Cases of Chronic HF According to the NYHA Functional Classes I-IV 19

Table 7: 7MM, Sources of Epidemiological Data Used for Forecast of HF Diagnosed Incident Cases of Acute HF Hospitalizations 20

Table 8: 7MM, Sources Not Used in Epidemiological Analysis of HF 35

Table 9: 7MM, Diagnosed Incident Cases of HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 37

Table 10: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, N (Row %), 2015 38

Table 11: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥45 Years, N (Row %), 2015 40

Table 12: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥45 Years, Both Sexes, N, 2015-2025 45

Table 13: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 47

Table 14: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 50

Table 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N (Row %), 2015 52

Table 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, N (Row %), 2015 54

List Of Figures, Charts and Diagrams
in EpiCast Report: Heart Failure - Epidemiology Forecast to 2025 [Published by Global Data]

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 37

Figure 2: 7MM, Diagnosed Incident Cases of HF by Age Group, Both Sexes, N, 2015 39

Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥45 Years, N, 2015 41

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Ages ≥45 Years, by Sex, 2015 42

Figure 5: 7MM, Diagnosed Incident Cases of HF Segmented by EF, Ages ≥45 Years, Both Sexes, N, 2015 43

Figure 6: 7MM, Diagnosed Incident Cases of HF Segmented by Ventricular Dysfunction, Ages ≥45 Years, Both Sexes, N, 2015 44

Figure 7: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥45 Years, Both Sexes, N, 2015-2025 45

Figure 8: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥45 Years, Both Sexes, N, 2015 46

Figure 9: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 48

Figure 10: 7MM, Hospital Length Of Stay For Acute HF Hospitalization, Ages ≥45 Years, Both Sexes, Days, 2015 49

Figure 11: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, Both Sexes, N, 2015-2025 51

Figure 12: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N, 2015 53

Figure 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, N, 2015 55

Figure 14: 7MM, Age-Standardized Diagnosed Prevalence of Chronic HF (%), Ages ≥45 Years, by Sex, 2015 56

Figure 15: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by EF, Ages ≥45 Years, Both Sexes, N, 2015 57

Figure 16: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by NYHA Classes, Ages ≥45 Years, Both Sexes, N, 2015 58

Figure 17: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by ACCF/AHA Stages, Ages ≥45 Years, Both Sexes, N, 2015 59

Figure 18: 7MM, Prevalent Cases of Comorbidities Among Diagnosed Prevalent Cases of Chronic HF, Both Sexes, Ages ≥45 Years, N, 2015 60

Additional Details

Publisher

Global Data

Publisher Information

Reference

26671 | GDHCER117-16

Number of Pages

77

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024SummaryNon-Hodgkin’s Lymphoma ...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024SummaryPulmonary Arte...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024SummarySmall Cell Lung Cancer ...
01 Jan 2016 by Global Data USD $3,995 More Info
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024SummaryThe Hepatitis B Virus (HBV...
24 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024SummaryRSV is a...
23 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024SummarySjögren’s syndrome (SS) is ...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024SummaryHuntington’s disease (HD)...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024SummarySystemic scle...
09 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,995 More Info
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

EpiCast Report: Heart Failure - Epidemiology Forecast to 2025 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)